Table 2.
Patient characteristics in the CAR group
| Characteristic | CAR | ||
|---|---|---|---|
| < 0.62 | ≥ 0.62 | ||
| n = 68 | n = 25 | p Value | |
| (%) | (%) | ||
| Age (years) | 69.0 [38–83] | 70 [42–85] | 0.57 |
| Median [range] | |||
| Sex | 53/15 | 19/6 | 1.00 |
| Male/Female | (78/22) | (76/24) | |
| Primary | 5/62/1 | 1/24/0 | 0.69 |
| Cervical/Thoracic/EGJ | (7/91/2) | (4/96/0) | |
| No. of metastatic sites | 51/17 | 16/9 | 0.31 |
| 1/ ≥ 2 | (75/25) | (64/36) | |
| Lung metastasis | 43/25 | 15/10 | 0.81 |
| No/Yes | (63/37) | (60/40) | |
| Liver metastasis | 48/20 | 18/7 | 1.00 |
| No/Yes | (70/30) | (72/28) | |
| Peritoneal metastasis | 66/2 | 23/2 | 0.29 |
| No/Yes | (97/3) | (92/8) | |
| Previous Surgery | 39/29 | 17/8 | 0.47 |
| No/Yes | (57/43) | (68/32) | |
| Previous Radiotherapy | 40/28 | 11/14 | 0.24 |
| No/Yes | (59/41) | (44/56) | |
| No. of previous regimens | 42/26 | 17/8 | 0.64 |
| 1/ ≥ 2 | (62/38) | (68/32) | |
| Received treatment after nivolumab | 31/37 | 16/9 | 0.16 |
| No/Yes | (46/54) | (64/36) | |
| BMI | 29/39 | 16/9 | 0.10 |
| < 18.5/ ≥ 18.5 | (43/57) | (64/36) | |
| ECOG PS | 34/34 | 8/17 | 0.16 |
| 0/ ≥ 1 | (50/50) | (32/68) | |
| Disease control | 44/24 | 18/7 | 0.62 |
| No/Yes | (65/35) | (72/28) | |
| Objective response | 55/13 | 20/5 | 1.00 |
| No/Yes | (80/20) | (80/20) | |
| irAE | 44/24 | 18/7 | 0.62 |
| No/Yes | (65/35) | (72/28) | |
p Value: Fisher’s exact test and the value of the comparison between the CAR group and the other groups. CAR, C-reactive protein/albumin ratio